52 results about "Pathologic" patented technology

The invention belongs to the technical field of biological medicines, and provides application of an ILDR3 gene and / or protein in preparation of medicines and diagnostic products for preventing and / or treating Tau-related diseases. The ILDR3 provided by the invention is a key therapeutic target of Tau-related diseases, and can simultaneously intervene a plurality of core links of Tau pathology, including promotion of Tau protein degradation, inhibition of excessive phosphorylation and blocking of abnormal aggregation of Tau protein. Test data show that expression of the ILDR3 in Tau related diseases is reduced, Tau pathology and cognitive impairment are aggravated by knocking out the ILDR3, and learning and memory functions of a Tau pathology model are remarkably improved and nerve injury is relieved by over-expression of the ILDR3. Therefore, the ILDR3 gene and / or protein can be applied to preparation of drugs and diagnostic products for preventing and / or treating Tau-related diseases.

The exemplified methods and systems facilitate the configuration and training of a neural network (e.g., a deep neural network, a convolutional neural network (CNN), etc.), or ensemble(s) thereof, with a biophysical signal data set to ascertain estimate for the presence or non-presence of disease or pathology in a subject as well as to assess and / or classify disease or pathology, including for example in some cases the severity of such disease or pathology, in a subject. In the context of the heart, the methods and systems described herein facilitate the configuration and training of a neural network, or ensemble(s) thereof, with a cardiac signal data set to ascertain estimate for the presence or non-presence of coronary artery disease or coronary pathology.

The present invention provides a method and system for evaluating various liver pathologies based on machine learning, which obtains the weight information, clinical examination information, and evaluation results of liver tissue samples of multiple historical patients; based on the obtained information, performs data preprocessing to construct a training set and a test set; uses the training set to train Logistic regression and Ridge regression models to determine the performance of the models in predicting ballooning degeneration, steatosis, lobular inflammation, significant fibrosis, and NASH, and determines the final prediction index parameters and prediction models; obtains the weight information, clinical examination information, and evaluation results of liver tissue samples of a patient, extracts the numerical values related to the prediction index parameters therefrom, and processes them with the determined trained prediction models for the corresponding prediction index parameters to obtain the final prediction results. The present invention constructs a simple model by obtaining clinical indicators and can comprehensively evaluate all aspects of the liver pathology of chronic liver diseases.

The invention relates to automatic pathology analysis by ultrasound imaging. Methods and systems for automatic classification, detection, assessment and / or diagnosis of pathologies in a subject determine the presence or absence and / or severity of various pathologies in the subject, such as the presence, absence and / or severity of aortic valve stenosis in the heart of the subject.

This is a monitoring approach that respects privacy (no routine biometric recognition) to continuously extract multimodal markers from individuals / patients. The system can use various modules, including cameras, microphones, connected objects, wearables, sensors, etc . . .. This allows for the early detection of ANY pathology whatsoever that can be detected in the continuous extraction of multimodal markers from individuals / patients and the rapid transmission of alerts to emergency medical services. The multimodal monitoring supported by AI algorithms will not only detect the QUALIFICATION of the onset of a pathology, but especially the QUANTIFICATION of this onset of pathology, and even more so to provide a KINETIC MEASURE OF THIS QUANTIFICATION over a significant period of time.ONLY in cases where a detected pathology requires urgent and absolute medical intervention, and if the precision levels of the methods employed have been validated by medical professionals, the approval of the protocol's performance by the medical authority can trigger the use of biometric recognition. The use of biometric recognition allows for access to the patient's medical history, which can strengthen the diagnosis to send an alarm AND / OR accelerate patient care by already having knowledge of their medical files upon arrival in the emergency room. THIS IS A CASE OF FORCE MAJEURE THAT REQUIRES URGENT TREATMENT, GOVERNED BY MEDICAL ETHICS, AND THEREFORE EXEMPT FROM ANY PRIOR AUTHORISATION.The use of biometric recognition may also be employed without prior approval from an authority ( MEDICAL OR OTHERWISE ), if and only if the state reliably detected by multimodal monitoring falls within the framework of the "OBLIGATION TO ASSIST A PERSON IN DANGER" according to the LAW, biometric recognition can then be used without prior authorization if it provides assistance in the diagnosis. Outside of the two cases mentioned above, "FORCE MAJEURE" AND / OR "OBLIGATION TO ASSIST A PERSON IN DANGER", the "Life Tracking Medicine", (LTM) which gives citizens the ability to create their own data heritage, allows for the CONSIDERATION OF THE PERSON’S PRIOR CONSENT at the time of the device's activation, ONLY IN CASE OF SUSPICION OF THE ARRIVAL / DETECTION OF ANY PATHLOGY, and without prior approval from an authority (MEDICAL OR OTHERWISE), for the use of biometric recognition.This case also includes persons who, being minors or lacking the capacity to make decisions, are represented by a Parent or legal guardian. In this context, the initial consent of the legal guardian will be taken into account, only in case of suspicion of the arrival / detection of any pathology.

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Systems and methods for the improved quantitative assessment of airway mucus plug pathology are provided herein which provide a quantitative suite of mucus imaging metrics that objectively quantifies features of mucus plug pathology in the lungs. Systems and methods for generating a subject-level mucus plug map that illustrates the position of one or more whole mucus plugs, or the absence of mucus plugs in an airway tree are discussed. Systems and methods for the determination of a subject-level mucus plug phenotype are provided herein.

A non-invasive ophthalmic light-based detection device for detecting pathologies associated with Alzheimer's disease (AD) in the retina of an eye. The device uses two imaging modalities, one of which directs a specific area to be interrogated by the second imaging modality. A hyperspectral reflectance imaging unit detects light reflected and / or backscattered from the retina from a broadband light source, which is used to determine one or more regions of interest. A Raman spectroscopy unit detects light from a laser that is re-emitted by the retina through the phenomenon of Raman scattering, which is targeted to the region of interest determined based on the hyperspectral reflectance information. The detection information from the hyperspectral reflectance imaging unit and the Raman spectroscopy unit is used to determine the presence of the one or more pathologies associated with AD. The detection device allows identification of high-risk groups, diagnosis and tracking of patient response to treatment.

The present invention relates to methods for characterising the pathology or state of a vascular region of a subject by: providing medical imaging data gathered along a length of a blood vessel and: determining radial segments of the vessel extending from a point in the centre of the vessel to a distance extending beyond the outer wall of the vessel to the perivascular region; determining a value for the radiodensity and / or one or more radiomic features of the radial segment; and comparing each value determined to a pre-determined value or using the absolute value, in order to generate an output value that indicates the pathology or state of the vascular region, or the inflammation of a plaque. At least one method step is computer implemented. The invention also provides a computer program product configured to carry out these methods, and to a system comprising one or processors to configured to perform the methods.

The present disclosure relates to a method of treating, preventing or delaying an age-related condition or pathology in a mammal using extracellular vesicles (EVs) derived from a young mammal.

The invention relates to negative functional modulators of at least one variant of the non-erythrogenic erythropoietin (V-EPO) and pharmaceutical compositions or kits containing them. Such functional negative modulators of V-EPO may be a mono- or multi-specific antibody anti-EV3, anti-EV4, anti-EV1-4, anti-EV1-5, anti-EV1-1, or EV2-1, or anti-Epo receptor (EpoR) anti-EPHB4, anti-CSF2RB, an antisense oligonucleotide, DNA decoy, RNA decoy, a ribozyme, an antagomiR, a shRNA, LNA or siRNA.Several uses of these functional modulators are described, which have been advantageously employed as a medicament and for the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing organ or tissue transplantation.The invention also describes variants of EPO for use in the diagnosis and in the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing an organ or tissue transplantation and as a diagnostic agent.According to another aspect, a monoclonal antibody to at least one of the variants of the erythropoietin is described.According to yet another aspect, the use of at least one alternative splicing variant of non-erythrogenic EPO and the measurement thereof at tissue and / or systemic level is described, as well as the study of the methylation status of the promoters of the genes involved in the EPO signalling pathway (by way of example EPO, EPOR, EPHB4, CSF2RB), as diagnostic, prognostic and predictive markers of an oncological pathology, a proliferative pathology, neurodegenerative or inflammatory pathology.

Described herein are EphA4 receptor antagonists, pharmaceutical compositions containing EphA4 antagonists, and methods and uses of treating an EphA4-based disease, disorder or pathology in an individual using EphA4 receptor antagonists.

A system is provided that includes a display and a processor in communication with the display. The processor is configured to receive an ultrasound video comprising a plurality of frames of an anatomical structure obtained by the ultrasound probe. The processor is further configured to generate at least one frame level metric for each frame detected to include a pathology based on the ultrasound video, and generate at least one video level metric related to the pathology based on the frame level metrics for the frames including the pathology. The processor is further configured to generate a video level classification of the pathology based on the video level metric related to the pathology and output it to the display.

A benzene sulfonamide compound of formula I or one of its addition salts with pharmaceutically acceptable acids, for use in a method of treating a pathology related to an excessive effect of TNF and for use in a method of treating the human or animal body.

The present invention pertains to a novel treatment of pathologies caused by an increased synthesis or accumulation of sulfolipids such as sulfatide. The invention provides mutated arylsulfatase A (ARSA or ASA, EC 3.1.6.8) enzymes with increased activity towards sulfatide metabolization. The invention provides nucleic acids encoding the mutant ARSA, the use of the proteins and nucleic acids, as well as pharmaceutical compositions comprising them, in the treatment of lysosomal storage disorders (LSDs) such as metachromatic leukodystrophy (MLD).

In some aspects, the described systems and methods provide for a method for training a deep learning model to assess liver pathology, including accessing annotated liver pathology images associated with a group of patients in one or more randomized controlled clinical trials of nonalcoholic steatohepatitis therapy, each of the annotated liver pathology images including at least one annotation describing one or more tissue characteristic categories for a portion of the image, and training the deep learning model based on the annotated liver pathology images to predict the tissue characteristic categories, selected from a group comprising steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis stage.

Described herein are various embodiments of techniques for determining reference values / ranges for diagnostic markers for patients during treatment and recovery during and / or after illness or injury. Some methods may include obtaining a patient's medical information (including any diagnosed medical conditions) and calculating, based on the medical condition and an elapsed time since onset or start of treatment, expected reference ranges for one or more diagnostic markers. These methods may also include outputting an indication of whether the measurements for the diagnostic marker or markers fall outside the reference range(s). In some embodiments, the reference values can be adjusted depending on additional pathologies indicated in the patient's medical information. Some such patient- and / or pathology-specific reference values / ranges can also be displayed to medical professionals to aid in patient care and / or leveraged in automated patient monitoring systems to alert doctors that a patient is not recovering according to the expected trajectory.

Determining vascular region pathology by: gathering medical imaging data along a length of a blood vessel; determining radial segments of the vessel, extending from the vessel centre to the perivascular region beyond the vessel’s outer wall; determining values for radiodensity and radiomic features of the radial segment; comparing the determined values with a pre-determined value to generate an output indicating pathology of the vascular region. Also disclosed: using the determined absolute value of radiodensity or radiomic features to generate the pathology indicating output. Also disclosed: identifying plaque voxels by their radiodensity. Computed tomography (CT) attenuation in perivascular adipose tissue (PVAT) may be determined. Vascular region texture or inflammation may be measured. Sub-clinical plaques, pre-plaque states or atherosclerotic disease may be identified. Calcified plaques may not be classified as inflamed. Inflamed plaques may be classified as fibrous, non-fibrous, hot, unstable, high risk. Threshold values may be adjusted based on age, gender, ethnicity, background adipocyte size, partial volume effects, blood vessel type, heart rate, heart rhythm, blood pressure, CT scanner tube voltage, reconstruction algorithms, iodinated contrast agent, contrast type, injection rate, aortic contrast opacification, left ventricular blood pool opacification, signal-to-noise, contrast-to-noise, milliamps, cardiac gating method, single and multiple energy image acquisition.

The present application discloses, as an embodiment of the invention, a compound, or a pharmaceutically acceptable salt thereof, that is useful as an agent for preventing or treating a disease caused by a decrease in autophagy function or a disease in which a pathological condition is suppressed or improved by the enhancement of autophagy function, and that is represented by formula (I) (in formula, the symbols are as described in the specification).

A computer-implemented system and method for predicting and diagnosing osteoporosis based on magnetic resonance imaging technology is disclosed. In particular, the method of the present invention is a reliable, reproducible and sensitive method for providing a reliable, reliable, reproducible and sensitive method for detecting, by simple and fast statistical processing, i.e. Only by statistically correlating recorded MRI of a subject with recorded MRI of a reference group, independent of other standard techniques such as, for example, clinical diagnosis of MOC, QCT, DXA or osteoporosis. Osteoporosis is predicted or diagnosed from the magnetic resonance image. In this aspect, any patient who experiences magnetic resonance imaging for reasons independent of osteoporosis can receive his / her diagnostic information about the medical state of osteoporosis, regardless of how, without additional studies or tests and without the use of ionizing radiation, regardless of the suspicion of the previous osteoporotic pathology. This is very valuable and ideal in that in this way, although the asymptomatic nature of osteoporosis, it is possible to early identify patients at risk of osteoporosis or in which pathology has progressed. In addition, the overall method of the invention is very convenient, so that neither the patient nor the national health system assumes additional expenses.

The present invention relates to compounds and compositions for use in a method of treating and / or preventing neurological or non-neurological channelopathies, i.e., pathologies which are caused specifically by defects in some of the calcium-activated potassium channels. Specific neurological channelopathies and / or synaptopathies targeted by the present invention include specific neuropsychiatric pathologies, such as particularly Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, autism, Autism spectrum disorders (ASDs), hyperacusis, Smith-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, and cri-du-chat syndrome, as well as other neuropathic disorders such as trembling, epilepsy and neuropathic pains associated and neurodegenerative diseases such as Parkinson's and Alzheimer diseases. Compounds, compositions and methods of the present invention are also particularly useful and efficient in alleviating neurological symptoms common to these neuropsychiatric pathologies.

The present disclosure generally relates to compositions and methods to increase resistance to age-related pathologies, improve physiological state or disorder related to cell ageing or metabolic fatigue in one or more cells; improve mobility and / or healthspan and / or lifespan of an adult animal in need. More specifically, the present disclosure relates to administering a formulation comprising an effective amount of nicotinamide (NAM) and Glycine, optionally an autophagy inducer.

Described herein are methods of assessing the risk of dementia in a subject using an odor-based test, or "smell test". These methods can be self-administered by the subject under the instruction of a computing device via a user interface. Methods of administering a smell test as described herein can optionally be combined with measuring and quantifying the level of at least one biomarker for dementia (e.g., CXCL10, CCL2, IL-6) in a biological sample collected from the subject. Also provided are methods to treat dementia (e.g., dementia associated with Alzheimer's disease, dementia associated with a subset of Alzheimer's disease patients with TDP-43 pathology).

Disclosed are 4-aminopyrrolo [2, I-f] [1, 2, 4] triazine compounds of Formula I for the treatment of various diseases and pathologies. More specifically, the present disclosure relates to the use of 4-aminopyrrolo [2, 1-f] [1, 2, 4] triazine compounds or analogs thereof in the treatment of conditions characterized by DYRK1A overexpression (e.g., cancer, Down's syndrome, Alzheimer's disease, diabetes, and osteoarthritis).

The present invention discloses a structure for magnetic coils that integrate a magnetic stimulation device, wherein the arrangement of a plurality of magnetic coils generates a vortex magnetic field to stimulate areas of interest, for example, towards the hippocampus in the brain of a subject in order to reduce Tau protein phosphorylation, which is an indicator of cognitive process pathologies such as memory loss, learning difficulties or diseases such as Alzheimer's disease. The present invention integrates a magnetic emitter based on modular magnetic coils to generate a vortex magnetic field, either around a body part of a subject or on their head, chest or abdomen. Alternatively, the magnetic stimulation device has cooling means that reduce the temperature of the magnetic coils during their operation, in a slim, portable structural configuration. Control means are used to adjust the characteristics of the desired magnetic field and the area where it is applied by controlling the power and frequency provided to each of them.

Compositions, methods, and kits are provided for diagnosing vitreoretinal diseases and age-related pathologies. In particular, aqueous humor biomarkers have been identified that correlate with biological aging and age-related pathologies and morbidity. The use of such biomarkers may allow earlier intervention in treatment of aging-related diseases. In addition, methods of using aqueous humor biomarkers for prognosis, diagnosis, and monitoring treatment of vitreoretinal diseases are also provided.

An antibody or antigen-binding fragment thereof having immunological reactivity with the MCEMP1 protein can be used as an active ingredient of a pharmaceutical composition for treating and / or preventing a disease in which mast cells expressing the MCEMP1 protein on the cell surfaces exacerbate the pathologic condition.

The present disclosure relates to a method for generating a trained classifier adapted to detect a targeted pathology in a body fluid sample, the method comprising: processing a set of body fluid samples each being associated with a presence indicator of the targeted pathology, to obtain processed samples each comprising a list of exRNAs comprising values representative of occurrence numbers of the exRNAs, detected in the body fluid sample; training machine learning models using the processed samples and a presence indicator of the targeted pathology associated with the processed samples; testing the trained machine learning models; generating a list of selected exRNA as a function of the scores attributed by the trained machine learning models; and training a classifier using the processed samples and the presence indicator of the targeted pathology, the trained classifier and the list of selected exRNA being used to detect the targeted pathology.

The invention provides a visual auxiliary diagnosis method and system for Alzheimer's disease pathology PET, and relates to the technical field of medical image processing.The method comprises the steps that a target PET image of a subject is preprocessed, and a preprocessed image is obtained; the preprocessed image is put into a trained antagonism decomposition learning model so as to decompose the preprocessed image, and a pathology probability graph and a diagnosis probability are generated based on a decomposition result; calculating an Alzheimer's disease resistance decomposition score based on a decomposition result of the resistance decomposition learning model, and performing visual evaluation in combination with the diagnosis probability to judge whether the subject is an Alzheimer's disease patient; and displaying the pathology probability graph in a thermodynamic diagram form so as to visually display the potential lesion area. Pathological and physiological uptake can be accurately decomposed, the accuracy and interpretability of AD diagnosis are improved, and meanwhile efficient human-machine collaborative pathological assessment is achieved.

The application belongs to the technical field of biological medicine, and provides application of ILDR3 gene and / or protein in preparation of a drug for preventing and / or treating a Tau-related disease and a diagnostic product. The ILDR3 provided in the application is a key treatment target of the Tau-related disease, can simultaneously intervene in multiple core links of the Tau pathology, including promoting degradation of the Tau protein, inhibiting excessive phosphorylation thereof and blocking abnormal aggregation thereof. Experimental data show that the expression of ILDR3 is down-regulated in the Tau-related disease, knocking out ILDR3 aggravates the Tau pathology and cognitive impairment, and overexpression of ILDR3 significantly improves learning and memory function of a Tau pathology model and reduces nerve damage. Therefore, the ILDR3 gene and / or protein can be applied to preparation of a drug for preventing and / or treating a Tau-related disease and a diagnostic product.